Prognostic factors associated with postprogression survival in advanced hepatocellular carcinoma patients treated with sorafenib not eligible for second-line regorafenib treatment

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Yoshiki Hirooka, Hidemi Goto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Fingerprint Dive into the research topics of 'Prognostic factors associated with postprogression survival in advanced hepatocellular carcinoma patients treated with sorafenib not eligible for second-line regorafenib treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences